Page 157 - 2020_01-Haematologica-web

The vascular niche in chronic myeloid leukemia
complete cytogenetic remission following imatinib mesylate treatment. Blood. 2003;101(12):4701-4707.
18. Chen B, Jiang L, Zhong ML, et al. Identification of fusion genes and characteri- zation of transcriptome features in T-cell acute lymphoblastic leukemia. Proc Natl Acad Sci U S A. 2018;115(2):373-378.
19. Lavender KJ, Pang WW, Messer RJ, et al. BLT-humanized C57BL/6 Rag2-/-γc-/-CD47- /- mice are resistant to GVHD and develop B- and T-cell immunity to HIV infection. Blood. 2013;122(25):4013-4020.
20. Li S, Ilaria RL, Million RP, Daley GQ, Van Etten RA. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leuke- mogenic activity. J Exp Med. 1999;189(9): 1399-1412.
21. Hu Y, Swerdlow S, Duffy TM, Weinmann R, Lee FY, Li S. Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice. Proc Natl Acad Sci U S A. 2006;103(45):16870-16875.
22. Chien S, Zhao X, Brown M, et al. A novel small molecule e-selectin inhibitor GMI- 1271 blocks adhesion of AML blasts to e- selectin and mobilizes blood cells in nodscid IL2Rgc−/− mice engrafted with human AML. Blood. 2012;120(21):4092.
23. Copland M, Hamilton A, Elrick LJ, et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in pri- mary CML but does not eliminate the quies- cent fraction. Blood. 2006;107(11):4532- 4539.
24. Chu S, Xu H, Shah NP, et al. Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment. Blood. 2005;105(5):2093-2098.
25. Dey S, Curtis DJ, Jane SM, Brandt SJ. The TAL1/SCL transcription factor regulates cell cycle progression and proliferation in diffe- rentiating murine bone marrow monocyte precursors. Mol Cell Biol. 2010;30(9): 2181- 2192.
26. Kolodziej S, Kuvardina ON, Oellerich T, et al. PADI4 acts as a coactivator of Tal1 by counteracting repressive histone arginine methylation. Nat Comm. 2014;5:3995.
27. Senbanjo LT, Chellaiah MA. CD44: a multi-
functional cell surface adhesion receptor is a regulator of progression and metastasis of cancer cells. Front Cell Dev Biol. 2017;5:18.
28. Branford S, Melo JV, Hughes TP. Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter? Blood. 2009;114(27):5426-5435.
CD44. J Biol Chem. 2008;283(46):31823-
31829.
38. Yu S, Cai X, Wu C, et al. Adhesion glycopro-
tein CD44 functions as an upstream regula- tor of a network connecting ERK, AKT and Hippo-YAP pathways in cancer progression. Oncotarget. 2015;6(5):2951-2965.
39. Rangaswami H, Bulbule A, Kundu GC. Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol. 2006;16: 79-
29. Nicolini FE, Ibrahim AR, Soverini S, et al.
The BCR-ABLT315I mutation compromises 87.
survival in chronic phase chronic myeloge- nous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis. Haematologica. 2013;98(10): 1510-1516.
30. Kumar R, Merten M, Minciacchi V, et al. Specific and targetable interactions with the bone marrow microenvironment govern out- come in imatinib-resistant chronic myeloid leukemia. Blood. 2018;132(Suppl 1):936.
31. Palamarchuk A, Efanov A, Maximov V, Aqeilan RI, Croce CM, Pekarsky Y. Akt phosphorylates Tal1 oncoprotein and inhibits its repressor activity. Cancer Res. 2005;65(11):4515-4519.
32. Skorski T, Kanakaraj P, Nieborowska- Skorska M, et al. Phosphatidylinositol 3- kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells. Blood. 1995;86 (2):726-736.
33. Atfi A, Abécassis L, Bourgeade MF. Bcr-Abl activates the AKT/Fox O3 signalling path- way to restrict transforming growth factor- beta-mediated cytostatic signals. EMBO Rep. 2005;6(10):985-991.
34. McWeeney SK, Pemberton LC, Loriaux MM, et al. A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib. Blood. 2010;115(2):315-325.
35. Radich JP, Dai H, Mao M, et al. Gene expres- sion changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci U S A. 2006;103(8):2794- 2799.
36. Lacombe J, Herblot S, Rojas-Sutterlin S, et al. Scl regulates the quiescence and the long- term competence of hematopoietic stem cells. Blood. 2010;115(4):792-803.
37. Kothapalli D, Flowers J, Xu T, Puré E, Assoian RK. Differential activation of ERK and Rac mediates the proliferative and anti- proliferative effects of hyaluronan and
40. Laird CT, Hassanein W, O'Neill NA, et al. P- and E-selectin receptor antagonism prevents human leukocyte adhesion to activated porcine endothelial monolayers and attenu- ates porcine endothelial damage. Xenotransplantation. 2018;25(2):e12381.
41. Zöller M. CD44, hyaluronan, the hematopoietic stem cell, and leukemia-initi- ating cells. Front Immunol. 2015;6:235.
42. Yan Y, Zuo X, Wei D. Concise review: emerging role of CD44 in cancer stem cells: a promising biomarker and therapeutic tar- get. Stem Cells Transl Med. 2015;4(9):1033- 1043.
43. Bendall LJ, Bradstock KF, Gottlieb DJ. Expression of CD44 variant exons in acute myeloid leukemia is more common and more complex than that observed in normal blood, bone marrow or CD34+ cells. Leukemia. 2000;14(7):1239-1246.
44. WangL,ZuoX,XieK,WeiD.Theroleof CD44 and cancer stem cells. Methods Mol Biol. 2018;1692:31-42.
45. Holm F, Hellqvist E, Mason CN, et al. Reversion to an embryonic alternative spli- cing program enhances leukemia stem cell self-renewal. Proc Natl Acad Sci U S A. 2015;112(50):15444-15449.
46. Borthakur G, Kantarjian H, Wang X, et al. Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimu- lating factor results in improved event-free survival. Cancer. 2008;113(11):3181-3185.
47. Holtz M, Forman SJ, Bhatia R. Growth fac- tor stimulation reduces residual quiescent chronic myelogenous leukemia progenitors remaining after imatinib treatment. Cancer Res. 2007;67:1113-1120.
48. Uy GL, Rettig MP, Motabi IH, et al. A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia. Blood. 2012;119(17):3917-3924.
haematologica | 2020; 105(1)
147